Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) EBITDA Margin (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed EBITDA Margin for 8 consecutive years, with 27.32% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 15566.0% year-over-year to 27.32%, compared with a TTM value of 59.1% through Dec 2025, up 30937.0%, and an annual FY2025 reading of 58.91%, up 30871.0% over the prior year.
  • EBITDA Margin was 27.32% for Q4 2025 at Zevra Therapeutics, up from 15.87% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 57.44% in Q1 2021 and bottomed at 51597.92% in Q2 2022.
  • Average EBITDA Margin over 5 years is 2790.53%, with a median of 120.95% recorded in 2023.
  • The sharpest move saw EBITDA Margin plummeted -5164658bps in 2022, then soared 5152410bps in 2023.
  • Year by year, EBITDA Margin stood at 110.07% in 2021, then plummeted by -263bps to 399.01% in 2022, then surged by 72bps to 113.55% in 2023, then decreased by -13bps to 128.34% in 2024, then skyrocketed by 121bps to 27.32% in 2025.
  • Business Quant data shows EBITDA Margin for ZVRA at 27.32% in Q4 2025, 15.87% in Q3 2025, and 274.29% in Q2 2025.